The order targets imported branded medicines, threatening pricing and supply-chain economics across the pharma sector and drawing pushback from manufacturers.

The agency's action date slips because of facility remediation issues rather than any problem with the clinical data, delaying a monthly prophylactic option for

The investment deepens AstraZeneca's partnership with Summit and expands its access to the bispecific ivonescimab program.

The adult vaccine's positive head-to-head immune response data against Pfizer's and Merck's shots supports Vaxcyte's bid to enter the competitive pneumococcal m

The licensing deal adds an oral GLP-1 asset to Novo's pipeline as it defends its obesity franchise against Lilly and other entrants.

The label expansion moves the BTK inhibitor into earlier lines of therapy, broadening its addressable leukemia population.

The manufacturing investment is intended to ease capacity constraints on Lilly's fast-growing obesity and diabetes drug supply.

An advisory committee vote will determine the regulatory fate of the company's cell therapy for Duchenne muscular dystrophy.

The agency's guidance toward a pre-BLA meeting gives Rezolute a path forward for its rare hypoglycemia drug even after the trial missed key goals.

The adjuvant survival benefit strengthens Tagrisso's position as the standard of care in EGFR-mutated early lung cancer.

The tie-up expands the transparent-pricing pharmacy's reach into employer-sponsored plans through a major health insurer.

The withdrawal of the daily liraglutide injection reflects a market shift toward longer-acting, more convenient obesity therapies.